HUTCHMED (HCM) Competitors $15.40 +0.01 (+0.06%) Closing price 04:00 PM EasternExtended Trading$15.40 0.00 (0.00%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HCM vs. MRNA, ROIV, QGEN, ELAN, BBIO, VRNA, RVMD, MRUS, RNA, and GRFSShould you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Moderna (MRNA), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Merus (MRUS), Avidity Biosciences (RNA), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. HUTCHMED vs. Its Competitors Moderna Roivant Sciences QIAGEN Elanco Animal Health BridgeBio Pharma Verona Pharma PLC American Depositary Share Revolution Medicines Merus Avidity Biosciences Grifols Moderna (NASDAQ:MRNA) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends. Is MRNA or HCM more profitable? HUTCHMED has a net margin of 0.00% compared to Moderna's net margin of -94.31%. HUTCHMED's return on equity of 0.00% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-94.31% -25.96% -20.09% HUTCHMED N/A N/A N/A Do institutionals & insiders have more ownership in MRNA or HCM? 75.3% of Moderna shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 11.0% of Moderna shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate MRNA or HCM? Moderna presently has a consensus target price of $40.93, suggesting a potential upside of 50.82%. HUTCHMED has a consensus target price of $20.88, suggesting a potential upside of 35.55%. Given Moderna's higher probable upside, analysts clearly believe Moderna is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 5 Sell rating(s) 13 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.00HUTCHMED 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer MRNA or HCM? In the previous week, Moderna had 11 more articles in the media than HUTCHMED. MarketBeat recorded 14 mentions for Moderna and 3 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.51 beat Moderna's score of 0.44 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, MRNA or HCM? HUTCHMED has lower revenue, but higher earnings than Moderna. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.06B3.47-$3.56B-$7.53-3.60HUTCHMED$602.20M4.46$37.73MN/AN/A Which has more volatility & risk, MRNA or HCM? Moderna has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. SummaryModerna beats HUTCHMED on 8 of the 14 factors compared between the two stocks. Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HCM vs. The Competition Export to ExcelMetricHUTCHMEDMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.69B$3.38B$6.13B$10.46BDividend YieldN/A2.30%5.73%4.78%P/E RatioN/A23.0785.1527.20Price / Sales4.46446.16574.61178.68Price / Cash52.6146.1137.3961.86Price / Book3.4810.5012.396.65Net Income$37.73M-$52.47M$3.32B$276.79M7 Day Performance-3.87%-1.00%-0.24%-1.51%1 Month Performance-11.70%14.49%9.56%5.46%1 Year Performance-22.26%13.92%71.67%36.25% HUTCHMED Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HCMHUTCHMED3.0767 of 5 stars$15.40+0.1%$20.88+35.6%-18.2%$2.69B$602.20M0.001,811MRNAModerna4.2364 of 5 stars$27.54-3.3%$41.81+51.8%-51.6%$11.08B$3.24B-3.665,800ROIVRoivant Sciences2.9843 of 5 stars$16.26+0.6%$19.94+22.6%+43.0%$11.04B$29.05M-23.23860Insider TradeQGENQIAGEN4.0743 of 5 stars$46.99+0.4%$49.40+5.1%+11.5%$10.40B$1.98B27.765,765Positive NewsELANElanco Animal Health2.4968 of 5 stars$20.68+0.2%$18.33-11.3%+47.1%$10.25B$4.44B24.059,000Analyst RevisionBBIOBridgeBio Pharma4.4381 of 5 stars$54.61+3.3%$63.94+17.1%+123.1%$10.11B$221.90M-13.35400Analyst RevisionVRNAVerona Pharma PLC American Depositary Share1.4419 of 5 stars$106.91+0.1%$109.00+2.0%N/A$9.20B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.2591 of 5 stars$46.58-0.3%$74.64+60.2%+1.2%$8.73B$11.58M-10.35250Analyst ForecastInsider TradeMRUSMerus1.5577 of 5 stars$94.270.0%$93.12-1.2%+84.9%$7.13B$56.23M-17.1437Short Interest ↓RNAAvidity Biosciences2.5737 of 5 stars$46.18-1.7%$68.32+47.9%+8.1%$6.86B$10.90M-12.97190GRFSGrifols3.5468 of 5 stars$9.61-3.4%$10.30+7.2%+12.7%$6.84B$7.81B8.2123,822 Related Companies and Tools Related Companies MRNA Alternatives ROIV Alternatives QGEN Alternatives ELAN Alternatives BBIO Alternatives VRNA Alternatives RVMD Alternatives MRUS Alternatives RNA Alternatives GRFS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HCM) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
